161 related articles for article (PubMed ID: 20652353)
41. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
42. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
43. Bi-allelic and tri-allelic 5-HTTLPR polymorphisms and triptan non-response in cluster headache.
Schürks M; Frahnow A; Diener HC; Kurth T; Rosskopf D; Grabe HJ
J Headache Pain; 2014 Jul; 15(1):46. PubMed ID: 25043824
[TBL] [Abstract][Full Text] [Related]
44. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms.
Velati D; Viana M; Cresta S; Mantegazza P; Testa L; Bettucci D; Rinaldi M; Sances G; Tassorelli C; Nappi G; Canonico PL; Martignoni E; Genazzani AA
Eur J Pharmacol; 2008 Feb; 580(1-2):43-7. PubMed ID: 18035351
[TBL] [Abstract][Full Text] [Related]
45. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
46. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
[TBL] [Abstract][Full Text] [Related]
47. Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan.
Wang TJ; Huang SY; Lin WW; Lo HY; Wu PL; Wang YS; Wu YS; Ko HC; Shih JC; Lu RB
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):108-14. PubMed ID: 17007976
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review.
Leroux E; Buchanan A; Lombard L; Loo LS; Bridge D; Rousseau B; Hopwood N; Matthews BR; Reuter U
Adv Ther; 2020 Dec; 37(12):4765-4796. PubMed ID: 32990921
[TBL] [Abstract][Full Text] [Related]
49. Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medication-Overuse Headache.
Lucchesi C; Baldacci F; Cafalli M; Chico L; Lo Gerfo A; Bonuccelli U; Siciliano G; Gori S
Headache; 2015; 55(7):984-91. PubMed ID: 26129705
[TBL] [Abstract][Full Text] [Related]
50. Pathways to the best fit of triptans for migraine patients.
Buzzi MG
Cephalalgia; 2008 Sep; 28 Suppl 2():21-7. PubMed ID: 18715329
[TBL] [Abstract][Full Text] [Related]
51. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine.
Vieira DS; Naffah-Mazzacoratti Mda G; Zukerman E; Senne Soares CA; Cavalheiro EA; Peres MF
Headache; 2007 Jun; 47(6):842-7. PubMed ID: 17578532
[TBL] [Abstract][Full Text] [Related]
52. MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence.
Contini V; Marques FZ; Garcia CE; Hutz MH; Bau CH
Am J Med Genet B Neuropsychiatr Genet; 2006 Apr; 141B(3):305-8. PubMed ID: 16526025
[TBL] [Abstract][Full Text] [Related]
53. Usage of triptans among migraine patients: an audit in nine GP practices.
Williams D; Cahill T; Dowson A; Fearon H; Lipscombe S; O'Sullivan E; Rees T; Strang C; Valori A; Watson D
Curr Med Res Opin; 2002; 18(1):1-9. PubMed ID: 11999139
[TBL] [Abstract][Full Text] [Related]
54. HPA axis function in male caregivers: effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR).
Brummett BH; Boyle SH; Siegler IC; Kuhn CM; Surwit RS; Garrett ME; Collins A; Ashley-Koch A; Williams RB
Biol Psychol; 2008 Oct; 79(2):250-5. PubMed ID: 18639608
[TBL] [Abstract][Full Text] [Related]
55. Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
Tauqeer F; Wood M; Hjorth S; Lupattelli A; Nordeng H
PLoS One; 2021; 16(8):e0256214. PubMed ID: 34424941
[TBL] [Abstract][Full Text] [Related]
56. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
57. Acute migraine treatment with oral triptans and NSAIDs in a managed care population.
Ng-Mak DS; Hu XH; Chen YT; Ma L
Headache; 2008 Sep; 48(8):1176-85. PubMed ID: 18819177
[TBL] [Abstract][Full Text] [Related]
58. Acute treatment patterns in patients with migraine newly initiating a triptan.
Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
[TBL] [Abstract][Full Text] [Related]
59. Acute management of migraine.
Chowdhury D
J Assoc Physicians India; 2010 Apr; 58 Suppl():21-5. PubMed ID: 21049703
[TBL] [Abstract][Full Text] [Related]
60. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.
Thorlund K; Mills EJ; Wu P; Ramos E; Chatterjee A; Druyts E; Goadsby PJ
Cephalalgia; 2014 Apr; 34(4):258-67. PubMed ID: 24108308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
